A matrix method for the evaluation of therapeutic agents: A framework based on disease process-oriented mechanisms of drug action and their effectiveness

Drug Information Journal

Volumn 31, Issue 1, 1997, Pages 105-110

  Bjornsson, Thorir D ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Effectiveness; Matrix; Specificity; Therapeutic agents

Indexed keywords

AMOXICILLIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DIGOXIN; EDROPHONIUM; HEPARIN; HEPATITIS B VACCINE; HYDROCHLOROTHIAZIDE; IMIPRAMINE; IPRATROPIUM BROMIDE; LEVODOPA; MERCAPTOPURINE; METHYLXANTHINE; MEVINOLIN; NEDOCROMIL; PARACETAMOL; PREDNISOLONE; PROPRANOLOL; SALBUTAMOL; TACRINE; TERFENADINE; THEOPHYLLINE; THIORIDAZINE; TRIAMCINOLONE;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLERGIC RHINITIS; ALZHEIMER DISEASE; ARTICLE; ASTHMA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HEADACHE; HEPATITIS B; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INHALATIONAL DRUG ADMINISTRATION; MYASTHENIA GRAVIS; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; UPPER RESPIRATORY TRACT INFECTION;

EID: 0031046316     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159703100116     Document Type: Article

References (15)

1. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Ninth edition. New York, NY: McGraw-Hill; 1996.
2. AHFS '96 Drug Information. Bethesda, MD: American Hospital Formulary Service, American Society of Hospital Pharmacists; 1996.
3. Guidelines for ATC Classification. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 1990.
4. How Drugs Work. User Guide. New York, NY: Pharmaprojects; 1994.
5. Grahme-Smith DG, Aronson JK. Oxford Textbook of Clinical Pharmacology and Drug Therapy. Oxford, England: Oxford University Press; 1992:55-66.
6. Bjornsson TD. A classification of drug action based on therapeutic effects. J Clin Pharmacol. 1996;36: 669-673.
7. NHLBI/WHO Workshop Report. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. National Institutes of Health, Publication Number 95-3659, 1995, pp. 70-117.
8. Freestone DS. Reflections on pharmaceutical company project portfolio management. Drug Inf J. 1994;28:641-646.
9. Spilker B. Evaluating a portfolio of investigational medicine projects. In: Spilker B. Multinational Pharmaceutical Companies. Principles and Practices. Second edition. New York, NY: Raven Press; 1994: 365-399.
10. Majaro S. Managing Ideas for Profit. The Creativity Gap. Maidenhead, Berkshire, England: McGraw-Hill International Ltd.; 1992:21-50.
11. Richey T. The Marketer's Visual Tool Kit. New York, NY: AMACOM; 1994.
12. Lidsone J, Collier T. Marketing Planning for the Pharmaceutical Industry. Aldershot, Hampshire, England: Gower Publishing Ltd.; 1987.
13. Beeson PB. Changes in medical therapy during the past century. Medicine. 1980;59:79-99.
14. Mossinghoff GJ. Health care reform and pharmaceutical innovation. Drug Inf J. 1995;29:1077-1090.
15. Wurtman RJ, Bettiker RL. The slowing of treatment discovery, 1965-1995. Nature Med. 1995;1:1122-1125.